End-of-day quote
Xetra
06:00:00 2024-02-04 pm EST
|
5-day change
|
1st Jan Change
|
1.89
EUR
|
-.--%
|
|
+8.31%
|
-.--%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
59.42
|
20.03
|
7.841
|
6.958
|
1.613
|
1.417
|
-
|
-
|
Enterprise Value (EV)
1 |
48.38
|
16.19
|
-15.21
|
-3.168
|
1.613
|
-0.7212
|
-0.2762
|
1.417
|
P/E ratio
|
-2.97
x
|
-1.68
x
|
-2.91
x
|
-0.57
x
|
-
|
-2.4
x
|
-2.42
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
52.8
x
|
23.8
x
|
1.26
x
|
14.3
x
|
4.75
x
|
9.45
x
|
-
|
-
|
EV / Revenue
|
43
x
|
19.3
x
|
-2.45
x
|
-6.53
x
|
4.75
x
|
-4.81
x
|
-
|
-
|
EV / EBITDA
|
-3.42
x
|
-1.46
x
|
7.86
x
|
0.28
x
|
-0.3
x
|
-1.8
x
|
-1.38
x
|
-
|
EV / FCF
|
-3.56
x
|
-1.69
x
|
3.63
x
|
0.25
x
|
-
|
-1.03
x
|
-2.76
x
|
-
|
FCF Yield
|
-28.1%
|
-59.2%
|
27.5%
|
406%
|
-
|
-97.1%
|
-36.2%
|
-
|
Price to Book
|
5.28
x
|
5.18
x
|
0.45
x
|
0.68
x
|
-
|
0.37
x
|
0.45
x
|
-
|
Nbr of stocks (in thousands)
|
272
|
295
|
612
|
819
|
853
|
880
|
-
|
-
|
Reference price
2 |
218.4
|
68.00
|
12.82
|
8.500
|
1.890
|
1.610
|
1.610
|
1.610
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
4/28/23
|
3/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.125
|
0.84
|
6.203
|
0.485
|
0.3392
|
0.15
|
-
|
-
|
EBITDA
1 |
-14.16
|
-11.09
|
-1.935
|
-11.3
|
-5.298
|
0.4
|
0.2
|
-
|
EBIT
1 |
-14.67
|
-11.63
|
-2.354
|
-12.05
|
-6.095
|
-0.54
|
-0.55
|
-
|
Operating Margin
|
-1,304.27%
|
-1,384.17%
|
-37.95%
|
-2,484.54%
|
-1,796.7%
|
-360%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.57
|
-11.66
|
-2.41
|
-12.1
|
-4.464
|
-0.59
|
-0.6
|
-
|
Net income
1 |
-17.02
|
-11.7
|
-2.428
|
-12.02
|
-4.464
|
-0.59
|
-0.6
|
-
|
Net margin
|
-1,512.89%
|
-1,392.86%
|
-39.14%
|
-2,479.18%
|
-1,315.78%
|
-393.33%
|
-
|
-
|
EPS
2 |
-73.60
|
-40.40
|
-4.400
|
-14.80
|
-
|
-0.6709
|
-0.6658
|
-
|
Free Cash Flow
1 |
-13.58
|
-9.581
|
-4.187
|
-12.87
|
-
|
0.7
|
0.1
|
-
|
FCF margin
|
-1,207.2%
|
-1,140.6%
|
-67.5%
|
-2,653.81%
|
-
|
466.67%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
175%
|
50%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
4/28/23
|
3/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
11
|
3.84
|
23
|
10.1
|
-
|
2.14
|
1.69
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-13.6
|
-9.58
|
-4.19
|
-12.9
|
-
|
0.7
|
0.1
|
-
|
ROE (net income / shareholders' equity)
|
-121%
|
-173%
|
-18.7%
|
-74.5%
|
-
|
-10%
|
-19.2%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
41.30
|
13.10
|
28.50
|
12.40
|
-
|
4.300
|
3.600
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.08
|
0.01
|
0.04
|
0.85
|
-
|
-
|
-
|
-
|
Capex / Sales
|
6.67%
|
1.19%
|
0.56%
|
174.64%
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/20
|
3/25/21
|
3/24/22
|
4/28/23
|
3/15/24
|
-
|
-
|
-
|
Last Close Price
1.61
EUR Average target price
16.85
EUR Spread / Average Target +946.58% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.45% | 10.82B | | +43.17% | 3.25B | | -35.86% | 2.11B | | -17.21% | 2.08B | | -29.81% | 1.48B | | +17.56% | 1.02B | | -4.37% | 733M | | -37.00% | 391M | | -46.94% | 383M |
Bio Diagnostics & Testing
|